ATRA诱导再分化在^(131)I治疗分化型甲状腺癌的应用研究  

The Application Research of All-trans-retinoic Acid-induced Redifferentiation in the Treatment of Differentiated Thyroid Carcinoma with ^(131)I

作　　者：张兰胜[1] 陈冬波[1] 王旭波[1] 张世强[1] 何苗[1] 

机构地区：[1]徐州医学院第二附属医院肿瘤科,江苏省徐州市221006

出　　处：《医学理论与实践》2008年第8期888-889,共2页The Journal of Medical Theory and Practice

摘　　要：目的:探讨全反式维甲酸(ATRA)在131I治疗分化型甲状腺癌中的应用价值。方法:22例甲状腺癌经全身131I扫描显示肺、骨转移灶摄碘能力低下,予口服ATRA 6~8周。比较ATRA治疗前后病灶摄碘的变化及血清甲状腺球蛋白(Tg)的变化。将碘摄取较前增加的病例归为治疗有效组,而碘摄取无变化的病例归为治疗无效组。结果:22例患者9例治疗有效。治疗有效组的中位Tg值较治疗无效组增高明显。结论:ATRA治疗能恢复或增强分化型甲状腺癌细胞的摄碘功能。Objective： To assess the value of iodine metabolism reinduced by ATRA. in treatment of differentiated thyroid carcinoma（DTC）. Methods： 22 patients were treated orally with ATRA for 6 -8 weeks before radioiodine（RI） therapy. All patients had insufficient or no radioiodine uptake in clinically important metastatic sites before RA therapy. The patients were grouped by comparing RI uptake post-RA with that preRA treatment. Student＇s t test was used for statistical analyses of serum thyroglobulin（Tg） levels. Results： 9/22 patients were responded to ATRA application with an increased RI uptake. Median Tg levels in the responder group was higher than that in the nonresponder group. Conclusion： RA does have an effect on differentiation status of DTC, reinducing RI uptake in some differentiated thyroid carcinoma.

关 键 词：全反式维甲酸 分化型甲状腺癌 再分化 放射性碘治疗 

分 类 号：R736.1[医药卫生—肿瘤]